# NEUROLMED Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurolmed-co

- Industry: Biotechnology
- Headquarters: Gyeonggi-do, South Korea
- Website: www.neurolmed.com
- Latest round: Seed (Feb 11, 2022)
- Investors on record: 4

## About

Founded in 2019 and based in Gyeonggi-do, South Korea, NEUROLMED Co., Ltd. is a biotechnology company that offers drugs designed to treat patients with central nervous system diseases. The company was founded by its CEO, Kang-Hoon Je. In February 2022, NEUROLMED raised seed funding from KB Investment.

NEUROLMED develops and offers drugs from biomolecules and natural products for chronic degenerative cerebral disorders, like stroke, Parkinson's disease, and Alzheimer's disease. The firm’s pipeline drug includes NRM-331, a small-molecule drug for cerebral ischemic reperfusion injury; NRM-205; NRM-021; and NRM-803. NeurolMed's AI platform uses computer science technology and next-generation semiconductor-based AI technology to solve new challenges in brain science.

## Funding rounds

- Seed, Feb 11, 2022 — KB Investment
- Seed, Oct 31, 2021 — Korea Tech Incubator for Startup, Venture Field
- Seed, Apr 14, 2021 — Ulsan Creative Economy Innovation Center

## Investors

- Ulsan Creative Economy Innovation Center (https://capitalatlas.ai/funds/ulsan-creative-economy-innovation-center) — Seed
- Korea Tech Incubator for Startup — Seed
- Venture Field (https://capitalatlas.ai/funds/venture-field) — Seed
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Seed